{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:45:46Z","timestamp":1761993946474,"version":"build-2065373602"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Veterinary Science"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.rvsc.2016.11.004","type":"journal-article","created":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T00:02:05Z","timestamp":1478563325000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Development of a plasminogen activator inhibitor (PAI-1) assay and comparison of plasma PAI-1 activity in hyperlipidemic\/dyslipidemic dogs with either hyperadrenocorticism or diabetes mellitus, and healthy dogs"],"prefix":"10.1016","volume":"111","author":[{"given":"Cheryl J.","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Koch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica L.","family":"Behling-Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rvsc.2016.11.004_bb0005","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1160\/TH07-11-0682","article-title":"Metabolic syndrome, haemostasis and thrombosis","volume":"99","author":"Alessi","year":"2008","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0010","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/01.CIR.79.1.101","article-title":"Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1)","volume":"79","author":"Angleton","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.rvsc.2016.11.004_bb0015","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.2741\/2285","article-title":"Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis","volume":"12","author":"Aso","year":"2007","journal-title":"Front. Biosci."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0020","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/vcp.12155","article-title":"Increases in beta-lipoproteins in hyperlipidemic and dyslipidemic dogs are associated with increased erythrocyte osmotic fragility","volume":"3","author":"Behling-Kelly","year":"2014","journal-title":"Vet. Clin. Pathol."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0025","first-page":"56","article-title":"Plasminogen activator inhibitor 1: physiological and pathophysiological roles","volume":"17","author":"Binder","year":"2002","journal-title":"News Physiol. Sci."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0030","unstructured":"Brant, R., n.d. Inference for means: comparing two independent samples [www document]. URL. http:\/\/www.stat.ubc.ca\/~rollin\/stats\/ssize\/n2.html (accessed 11.8.16)."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0035","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.thromres.2008.04.008","article-title":"Heterogeneous glycosylation patterns of human PAI-1 may reveal its cellular origin","volume":"122","author":"Brogren","year":"2008","journal-title":"Thromb. Res."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0040","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/jvim.12270","article-title":"Serum adipokine concentrations in dogs with naturally occurring pituitary-dependent hyperadrenocorticism","volume":"28","author":"Cho","year":"2014","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0045","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/nat.2013.0475","article-title":"Inhibition of PAI-1 antiproteolytic activity against tPA by RNA aptamers","volume":"24","author":"Damare","year":"2014","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0050","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejvs.2006.10.006","article-title":"Obesity and thrombosis","volume":"33","author":"Darvall","year":"2007","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0055","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.tcam.2012.07.002","article-title":"Diseases associated with thrombosis","volume":"27","author":"de Laforcade","year":"2012","journal-title":"Top. Companion Anim. Med."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0060","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1042\/cs1040357","article-title":"Comparison between the effects of mixed dyslipidaemia and hypercholesterolaemia on endothelial function, atherosclerotic lesions and fibrinolysis in rabbits","volume":"104","author":"de las Heras","year":"2003","journal-title":"Clin. Sci. (Lond.)"},{"key":"10.1016\/j.rvsc.2016.11.004_bb0065","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1055\/s-0033-1334487","article-title":"Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin","volume":"39","author":"Declerck","year":"2013","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0070","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jsb.2010.03.006","article-title":"Subtle structural differences between human and mouse PAI-1 reveal the basis for biochemical differences","volume":"171","author":"Dewilde","year":"2010","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0075","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.jvs.2011.08.038","article-title":"Impaired fibrinolytic system in ApoE null mice with hyperlipidemia augments deep vein thrombosis","volume":"55","author":"Diaz","year":"2012","journal-title":"J. Vasc. Surg."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0080","unstructured":"EMD Millipore, 2016. CC4075|human plasminogen activator inhibitor-1, recombinant [www document]. URL http:\/\/www.emdmillipore.com\/US\/en\/product\/Human-Plasminogen-activator-inhibitor-1%2C-recombinant,MM_NF-CC4075 (accessed 11.8.16)."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0085","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2460\/ajvr.75.8.731","article-title":"Evaluation of tranexamic acid and \u03b5-aminocaproic acid concentrations required to inhibit fibrinolysis in plasma of dogs and humans","volume":"75","author":"Fletcher","year":"2014","journal-title":"Am. J. Vet. Res."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0090","unstructured":"Genentech Inc., n.d. Activase (Alteplase) Full Prescribing Information [WWW Document]. URL http:\/\/www.gene.com\/download\/pdf\/activase_prescribing.pdf (accessed 7.7.15)."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0095","series-title":"Biochemical Basis for the Hypercoagulable State Seen in Cushing Syndrome","first-page":"136","author":"Gosselin","year":"2001"},{"key":"10.1016\/j.rvsc.2016.11.004_bb0100","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/35038119","article-title":"Structure of a serpin-protease complex shows inhibition by deformation","volume":"407","author":"Huntington","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.rvsc.2016.11.004_bb0105","first-page":"361","article-title":"Hyperlipidemia disorders in dogs","volume":"27","author":"Johnson","year":"2005","journal-title":"Compend. Contin. Educ. Pract. Vet."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0110","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.atherosclerosis.2004.01.026","article-title":"Interrelationships between the fibrinolytic system and lipoproteins in the pathogenesis of coronary atherosclerosis","volume":"174","author":"Jovin","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.rvsc.2016.11.004_bb0115","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1399-0039.2006.00716.x","article-title":"Identification of susceptibility and protective major histocompatibility complex haplotypes in canine diabetes mellitus","volume":"68","author":"Kennedy","year":"2006","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.rvsc.2016.11.004_bb0120","series-title":"Update 1996: Blood Collection and Handling Procedures for Assessment of Plasminogen Activators and Inhibitors (Leiden Fibrinolysis Workshop)","first-page":"171","author":"Kluft","year":"1996"},{"key":"10.1016\/j.rvsc.2016.11.004_bb0125","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1182\/blood-2010-03-276170","article-title":"A revised model for the secretion of tPA and cytokines from cultured endothelial cells","volume":"116","author":"Knipe","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.rvsc.2016.11.004_bb0130","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/ajcp\/89.6.747","article-title":"Plasminogen activator and plasminogen activator inhibitor activities in a reference population","volume":"89","author":"Krishnamurti","year":"1988","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0135","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1182\/blood.V86.11.4007.bloodjournal86114007","article-title":"Biological and clinical aspects of plasminogen activator inhibitor type 2","volume":"86","author":"Kruithof","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.rvsc.2016.11.004_bb0140","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.2460\/ajvr.1996.57.08.1124","article-title":"Evaluation of chromogenic substrate assays for fibrinolytic analytes in dogs","volume":"57","author":"Lanevschi","year":"1996","journal-title":"Am. J. Vet. Res."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0145","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1538-7836.2004.00827.x","article-title":"Pleiotropic functions of plasminogen activator inhibitor-1","volume":"3","author":"Lijnen","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0150","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1055\/s-2007-1005038","article-title":"Interaction of plasminogen activators and inhibitors with plasminogen and fibrin","volume":"8","author":"Lijnen","year":"1982","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0155","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.rvsc.2014.07.014","article-title":"Involvement of glucagon-like peptide 1 in the glucose homeostasis regulation in obese and pituitary-dependent hyperadrenocorticism affected dogs","volume":"97","author":"Miceli","year":"2014","journal-title":"Res. Vet. Sci."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0160","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2337\/diabetes.48.4.890","article-title":"Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue","volume":"48","author":"Morange","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.rvsc.2016.11.004_bb0165","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-14-0202","article-title":"Animal models of disease: classification and etiology of diabetes in dogs and cats","volume":"222","author":"Nelson","year":"2014","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0170","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1080\/07420520701534673","article-title":"Circadian variations in coagulation and fibrinolytic factors among four different strains of mice","volume":"24","author":"Ohkura","year":"2007","journal-title":"Chronobiol. Int."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0175","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/00001721-199212000-00013","article-title":"The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state","volume":"3","author":"Patrassi","year":"1992","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.rvsc.2016.11.004_bb0180","doi-asserted-by":"crossref","first-page":"48197","DOI":"10.1074\/jbc.M306184200","article-title":"Distortion of the catalytic domain of tissue-type plasminogen activator by plasminogen activator inhibitor-1 coincides with the formation of stable serpin-proteinase complexes","volume":"278","author":"Perron","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0185","series-title":"Portal Vein Thrombosis in 33 Dogs: 1998\u20132011","first-page":"230","author":"Respess","year":"2012"},{"key":"10.1016\/j.rvsc.2016.11.004_bb0190","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1538-7836.2008.03220.x","article-title":"New insights into the molecular mechanisms of the fibrinolytic system","volume":"7","author":"Rijken","year":"2009","journal-title":"J. Thromb. Haemost."},{"year":"2011","series-title":"Rho-Kinase Mediates Hyperglycemia-Induced Plasminogen Activator Inhibitor-1 Expression in Vascular Endothelial Cells 4, 3261\u20133268","author":"Rikitake","key":"10.1016\/j.rvsc.2016.11.004_bb0195"},{"key":"10.1016\/j.rvsc.2016.11.004_bb0200","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00018-010-0566-5","article-title":"The plasmin-antiplasmin system: structural and functional aspects","volume":"68","author":"Schaller","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0205","first-page":"R1563","article-title":"Tissue-specific PAI-1 gene expression and glycosylation pattern in insulin-resistant old rats","volume":"297","author":"Serrano","year":"2009","journal-title":"Am. J. Phys. Regul. Integr. Comp. Phys."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0210","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0009-8981(97)06517-0","article-title":"The effect of chemical anti-inhibitors on fibrinolytic enzymes and inhibitors","volume":"261","author":"Sidelmann","year":"1997","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.rvsc.2016.11.004_bb0215","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/vcp.12068","article-title":"Endogenous fibrinolytic potential in tissue-plasminogen activator-modified thromboelastography analysis is significantly decreased in dogs suffering from diseases predisposing to thrombosis","volume":"42","author":"Spodsberg","year":"2013","journal-title":"Vet. Clin. Pathol."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0220","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0049-3848(93)90005-9","article-title":"Fibrinolytic response to venous occlusion in healthy subjects: relationship to age, gender, body weight, blood lipids and insulin","volume":"69","author":"Stegnar","year":"1993","journal-title":"Thromb. Res."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0225","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/0895-4356(89)90067-X","article-title":"Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: a cross-sectional study in Norsj\u00f6, Sweden","volume":"42","author":"Sundell","year":"1989","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0230","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1538-7836.2007.02422.x","article-title":"The regulation by fibrinogen and fibrin of tissue plasminogen activator kinetics and inhibition by plasminogen activator inhibitor 1","volume":"5","author":"Thelwell","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0235","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.bbrc.2009.10.066","article-title":"Irreversibly glycated LDL induce oxidative and inflammatory state in human endothelial cells; added effect of high glucose","volume":"390","author":"Toma","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0240","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1055\/s-2002-38257","article-title":"Glucocorticoid-regulated adipose tissue secretion of PAI-1, but not IL-6, TNF\u03b1 or leptin in vivo","volume":"34","author":"Udd\u00e9n","year":"2002","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0245","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1210\/jc.2011-2753","article-title":"The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy","volume":"97","author":"Van Der Pas","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.rvsc.2016.11.004_bb0250","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1055\/s-0037-1613860","article-title":"Role of gender and genetic variance in plasminogen activator inhibitor-1 secretion from human adipose tissue","volume":"83","author":"van Harmelen","year":"2000","journal-title":"Thromb. Haemost."},{"year":"2014","series-title":"Functional Stability of Plasminogen Activator Inhibitor-1 2014","author":"Yildiz","key":"10.1016\/j.rvsc.2016.11.004_bb0255"},{"key":"10.1016\/j.rvsc.2016.11.004_bb0260","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.2337\/db06-1199","article-title":"Involvement of heat shock factor-1 in glycated LDL\u2013induced upregulation of plasminogen activator inhibitor-1 in vascular endothelial cells","volume":"56","author":"Zhao","year":"2007","journal-title":"Diabetes"}],"container-title":["Research in Veterinary Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034528816305793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0034528816305793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T04:05:02Z","timestamp":1758513902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0034528816305793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":52,"alternative-id":["S0034528816305793"],"URL":"https:\/\/doi.org\/10.1016\/j.rvsc.2016.11.004","relation":{},"ISSN":["0034-5288"],"issn-type":[{"type":"print","value":"0034-5288"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a plasminogen activator inhibitor (PAI-1) assay and comparison of plasma PAI-1 activity in hyperlipidemic\/dyslipidemic dogs with either hyperadrenocorticism or diabetes mellitus, and healthy dogs","name":"articletitle","label":"Article Title"},{"value":"Research in Veterinary Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rvsc.2016.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}